Clinical Center of the University of Sarajevo Neuroendocrine carcinoma of the breast: A retrospective review 2005-2016 Faruk Skenderi, Nurija Bilalovic, Vanesa Beslagic, Edina Balta, Berisa Hasanbegovic, Semir Beslija, Semir Vranic Clinical Center of the University of Sarajevo 3rd CONGRESS OF PATHOLOGISTS OF BOSNIA AND HERZEGOVINA 2-3 November 2016, Sarajevo, Bosnia and Herzegovina

INTRODUCTION Neuroendocrine carcinoma of the breast is a rare entity (<1% of all breast carcinomas) No data from prospective clinical trials on its optimal management Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer Inno A. et al. The Oncologist 2016;21:28–32

INTRODUCTION Differences between the 3rd and 4th edition of the WHO classification of the neuroendocrine breast tumors. Jurcic P. et al. Endocrine Oncology and Metabolism 2016;21:28–32

Neuroendocrine breast carcioma (NEC) Neuroendocrine architecture and cytomorphology May have mucinous areas

Neuroendocrine breast carcioma (NEC) Neuroendocrine architecture and cytomorphology

Neuroendocrine breast carcioma (NEC) Neuroendocrine cytomorphology

Progesterone receptor Chromogranin-A Synaptophysin Estrogen receptor Progesterone receptor

Neuroendocrine breast carcioma (NEC) Methods Retrospective analysis of medical records from 2005 to 2016 Clinical, morphological and immunohistochemical characteristics evaluated

Neuroendocrine breast carcioma (NEC) Clinical and pathological data Retrospective analysis of pathological and oncological records from 2005 to 2016 2374 breast carcinomas (68/100 000 population/year) 12 cases of NEC (0.5%) Average age 65.3 years (range 50-83 years) Most affected age group 61-70 years (33%)

Neuroendocrine breast carcioma (NEC) Clinical data 2374 breast carcinomas (68/100 000 population/year) 12 cases of NEC (0.5%) Average age 65.3 years (range 50-83 years) Most affected age group 61-70 years (33%)

Neuroendocrine breast carcioma (NEC) Pathological data Grade 2 and 3: 87% pT2 (8/12, 67%) pT1 (3/12, 25%) pT4 (1/12, 8%).

Neuroendocrine breast carcioma (NEC) Immunohistochemistry Synaptophysin and chromogranin-A: 92% positive Estrogen and progesterone receptors: 100% positive Her-2/neu: 8% (1 case) positive

Neuroendocrine breast carcioma (NEC) Outcome Median follow-up 7 years (range, 0-10 years) No evidence of disease 8/12 (67%) Alive with disease 1/12 (8%) Died of disease 3/12 (25%) in stage pT4 or disease with comorbidity in stage pT2

CONCLUSIONS NEC in Bosnia and Herzegovina is rare Affects slightly older patient population than ductal breast carcinoma Breast NEC is ER and PR positive Breast NEC is associated with a favorable clinical course and outcome, but this is stage-dependent.

THANK YOU FOR YOUR ATTENTION